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Objective: Faecal calprotectin is used as a sensitive
marker for gastrointestinal mucosal inflammation. We
compared the performance of three different assays in
a large cohort of symptomatic paediatric patients.
Design: Retrospective monocentric study.
Setting: Inpatients and outpatients of a tertiary referral
centre for paediatric gastroenterology.
Participants: 304 symptomatic patients (163 males,
aged 2–20 years) with active inflammatory bowel
disease (IBD/A, n=130), IBD in clinical remission (IBD/
R, n=62), other intestinal diseases (n=45) and controls
without identified intestinal disease (n=67).
Interventions: Calprotectin was measured in
homogenised faecal samples with three tests (A: EliA
Calprotectin, Phadia AB, Sweden; B: PhiCal, Calpro AS,
Norway; C: EK-Cal, Bühlmann Laboratories,
Switzerland).
Outcomes: Concordance between tests was calculated
using Kendall’s τ coefficient.
Results: IBD/A and controls were correctly classified
as 97.7%/82.1% (A), 97.7%/85.1% (B) and 98.4%/
62.7% (C; not significant). Test C tended to have
higher calprotectin values with a lower specificity
compared to tests A and B. The concordance between
two tests was 0.835 for tests A and B, 0.782 for tests
A and C and 0.765 for tests B and C.
Conclusions: All three tests are very sensitive for
detecting mucosal inflammation, but major differences
exist between specificity and absolute values. It is
highly advisable to use the test of the same
manufacturer for follow-up and to monitor for disease
activity.
INTRODUCTION
Faecal calprotectin (FC) is a sensitive, non-
invasive marker for mucosal inflammation. It
is a small calcium-binding protein belonging
to the S100 family1 and accounts for 60% of
the cytosolic proteins in neutrophilic granulo-
cytes, but is also found in smaller parts in
monocytes and macrophages.2 It is considered
to have bactericidal and fungicidal properties.3
Elevated calprotectin concentrations are
reported in plasma, synovial fluid, urine and
faeces if there is an ongoing inflammation
with recruitment of neutrophils.4 The advan-
tage of FC measurement is the stability in stool
samples of up to 7 days at room temperature
which makes stool collection and transporta-
tion simple and feasible.3 Increased FC con-
centrations have been found in several
inflammatory gastrointestinal (GI) diseases
including gastric cancer, colorectal cancer and
colonic polyps, as well as in chronic inflamma-
tory bowel disease (IBD),3 allergic colitis,5
Strengths and limitations of this study
▪ Faecal calprotectin (FC) is a sensitive, non-
invasive marker for mucosal inflammation. It is
used to screen symptomatic patients and to
monitor success of anti-inflammatory treatment
and relapse in patients with inflammatory bowel
disease. FC concentrations are superior to
predict mucosal inflammation compared to
inflammatory blood values such as C reactive
protein or erythrocyte sedimentation rate.
▪ To date studies on head-to-head comparisons of
different calprotectin assays in symptomatic chil-
dren are lacking. FC tests from three manufac-
turers were performed on homogenised stool
samples in 304 paediatric patients.
▪ The different tests revealed remarkably different
FC concentrations on the same stool sample.
This intertest variability may have impact on clinical
decision-making regarding further workup or
treatment escalation. Therefore, a test of the
same manufacturer should be used for follow-up
and to monitor for disease activity.
▪ Since endoscopies had not been performed in
most children, we cannot judge whether one test
is superior to reflect severity and extension of
mucosal inflammation.
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necrotising enterocolitis6 and cystic fibrosis.7 Increased FC
concentrations can be considered as inflammation spe-
cific, but not disease specific. In paediatric patients FC has
an excellent sensitivity for detection of new, untreated
paediatric patients with active IBD.8 9 A recent
meta-analysis of the diagnostic accuracy of FC during the
investigation of suspected paediatric IBD including eight
studies with 394 children with IBD and 321 controls
showed a pooled sensitivity of 0.978 (95% CI 0.947 to
0.996) with a negative likelihood ratio of 0.03. These excel-
lent values have significantly reduced the number of inva-
sive methods necessary for the diagnostic workup in
children presenting with GI symptoms. In addition, FC is
commonly used to monitor the success of treatment and
to predict relapse in patients with IBD.10–12 While several
studies compared the performance of different faecal
markers,13–15 published data are scarce to compare the
performance of different FC tests in the same faecal
samples. The majority of commercially available tests use a
cut-off of 50 µg/g stool between normal and elevated
values, and values between 50 and 100 µg/g are consid-
ered as borderline. A low intertest variability regarding
normal, borderline, moderate and high elevated levels is
crucial when clinicians make decisions based on the
results of FC concentrations. The aim of the study was to
compare head to head the results of one fluorescence
enzyme immunoassay (FEIA) and two ELISA in a large
cohort of unselected paediatric patients who were investi-
gated for FC in our institution because of different
symptoms.
PATIENTS AND METHODS
We retrospectively investigated stool samples of symp-
tomatic children and adolescents that had been seen as
inpatients or outpatients in the Dr. v. Hauner Children’s
Hospital from December 2009 to September 2011 and
in which the caring physician had ordered a test for FC.
Patients with multiple measurements were only consid-
ered for their first sample. After the initial determin-
ation for clinical purposes faecal samples were frozen at
−20°C up to 18 months before analysis. The patients’
final diagnoses were extracted from the hospital charts.
Patients were excluded when there was insufficient clin-
ical information on the final diagnosis or if they were
younger than 2 years of age, because particularly infants
are known to have high FC levels in the absence of
disease.16 17 In patients with proven IBD the disease
activity at the time of stool sampling was judged by a
paediatric gastroenterologist as clinical remission or
active disease based on clinical history and physical
examination. Patients were classified into four groups:
patients with newly diagnosed or relapsed active IBD
(group 1), IBD in remission (group 2), children with
another confirmed intestinal pathology (group 3, mixed
disease) and control children with no finding at the
time of measurement or during follow-up indicating an
organic GI disorder (group 4, controls).
Coded faecal samples were measured for calprotectin
concentrations using one FEIA (test A: EliA
Calprotectin, Phadia AB, Sweden) and two different
ELISA tests (test B: PhiCal, Calpro AS, Norway; test C:
EK-Cal, Bühlmann Laboratories, Switzerland). Faecal
samples were homogenised prior to extraction.
Homogenised samples were extracted separately for kits
A, B and C according to the respective manufacturers’
directions for use, using the ‘Faecal sample preparation
kit’ (Roche Diagnostics, Germany). Sample extracts were
assayed according to respective manufacturers’ direc-
tions for use. The cut-off value between negative and
positive given by the manufacturer was 50 µg/g for all
three tests. The lowest and highest values measurable
with tests A, B and C were 15, 19.5 and 30 µg/g and
3000, 2500 and 1800 µg/g, respectively. Values above the
maximal measurable concentration were not further
diluted in order to obtain the exact concentration.
Statistical analysis was performed using SAS V.9.2 (SAS
Institute Inc, Cary, North Carolina, USA); FC concentra-
tions for the three tests are given as boxplots.
Additionally, test results were divided according to their
FC concentration into five clinical meaningful categor-
ies: normal (<50 µg/g), borderline (50–100 µg/g), mod-
erately high (100–250 µg/g), high (250–1000 µg/g) and
very high (>1000 µg/g). Concordance between two tests
in these five categories was assessed using Kendall’s τ
coefficient. For comparison with clinical diagnoses, cat-
egories >100 µg/g were combined. Sensitivities referring
to active IBD and specificities referring to healthy con-
trols were calculated for the recommended cut-off of
50 µg/g. The diagnostic performance of the different
tests was further analysed over the whole range of pos-
sible cut-off values by calculating the area under the




Of 344 samples measured, 21 were excluded because
there was insufficient material available for all three
tests; another 19 children were younger than 2 years of
age. The final cohort included 304 patients (163 males,
141 females) with a median age of 14 years (range 2.0–
20.8). The numbers of children classified to the four
groups 1– 4 (IBD active, IBD in remission, other GI dis-
eases and controls) were 130, 62, 45 and 67 cases,
respectively. Patient characteristics are given in table 1.
The diagnoses in patients from group 3 (other GI
disease) included challenge-proven food allergy (n=15),
infectious gastroenteritis (n=8), bowel resection (short
bowel syndrome, Hirschsprung’s disease, n=12), immuno-
deficiency disorders with GI involvement (n=3), auto-
immune enteropathy and untreated coeliac disease (n=5),
vascular malformations (n=2) and ulcerations due to non-
steroidal anti-inflammatory drugs intake (n=1). In the
control group the majority of patients were finally
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diagnosed to have functional disorders (irritable bowel
syndrome, dyspepsia and constipation, n=55), carbohy-
drate maldigestion/absorption (lactose, fructose, n=5),
Gilbert’s syndrome (n=2), children screened because of
chronic recurrent multifocal osteomyelitis (n=3) and
coeliac disease on a gluten-free diet (n=2).
Concentrations of FC
Distribution of FC values is shown in figure 1 for the
three different assays (A, B and C) in the four different
diagnostic groups. There was a clear tendency towards
higher values in test C compared to tests A and B.
Table 2 gives the percentage of children in the differ-
ent diagnostic groups (1–4) having FC values <50 µg/g
(normal), 50–100 µg/g (borderline) and >100 µg/g
(increased) for the three different tests. Four children
with treated Crohn’s disease were classified by their phy-
sicians as having active IBD, but they had normal or bor-
derline values for FC in all three tests (figure 1). In
contrast, none of the 28 newly diagnosed patients with
IBD had a value below 100 µg/g. Ten of 19 excluded
infants and toddlers younger than 2 years had FC values
<100 µg/g, and the remaining 9 children showed ele-
vated values >100 µg/g, again with a clear tendency
towards higher values in test C (data not shown).
Calculated sensitivity values to diagnose active IBD
using the recommended cut-off of 50 µg/g were 97.7%,
97.7% and 98.4% for tests A, B and C, respectively
(table 2). Specificity (calculated for symptomatic con-
trols with no identified GI disease in group 4) using the
recommended cut-off was 82.1%, 85.1% and 62.7% for
tests A, B and C, respectively.
ROC analyses were performed to identify patients with
active IBD compared to controls of group 4 for tests A,
B and C and resulted in an AUC (95% CI) of 0.979
(0.956 to 100), 0.973 (0.949 to 0.998) and 0.970 (0.942
to 0.998), respectively (no significant difference between
the 3 tests).
When we compared the test results in the five categor-
ies of FC concentrations we found a better concordance
between tests A and B, compared to A and C and B and
C (table 3). A difference of one category was found in
102, 103 and 138 samples, while a difference of more
than one categories was observed in 11, 18 and 19 cases
(table 3, panel D). The calculated concordance between
two tests using the Kendall’s τ coefficient was 0.835 for
tests A and B, 0.782 for tests A and C and 0.765 for tests
B and C.
DISCUSSION
Detection of FC is an important diagnostic tool to
screen for GI inflammation or to monitor success of
therapy in patients with IBD. This non-invasive method
is particularly suitable in paediatric patients in order to
reduce the need for endoscopies. For clinical decision-
making it is important to have a high sensitivity to detect
children with undiagnosed IBD who present with unspe-
cific symptoms such as abdominal pain or chronic diar-
rhoea. On the other hand, a low specificity will increase
the number of endoscopies, follow-up investigations in
children with self-limiting disease such as GI infections,
or treatment escalation in patients with IBD. Several
tests for the measurement of FC are commercially avail-
able. Studies so far on head-to-head comparisons of dif-
ferent calprotectin assays in symptomatic children are
lacking. We compared the results of two conventional
ELISAs and a newly developed FEIA in a large represen-
tative cohort of 304 paediatric patients. We excluded
infants and young children below 2 years of age from
our analysis, because increased FC concentrations have
been reported in this age group in the absence of any
disease.17 18
Table 1 Patients’ characteristics for group 1–4
Group Diagnosis N Male, n (%) Median (years) Minimum (years) Maximum (years)
1 IBD active 130 74 (57) 15.0 4.3 20.8
2 IBD in remission 62 32 (52) 15.7 6.2 20.3
3 Other GI disease 45 27 (60) 7.8 2.0 20.1
4 Controls 67 30 (45) 11.3 2.2 17.5
GI, gastrointestinal; IBD, inflammatory bowel disease.
Figure 1 Distribution of faecal calprotectin concentrations (µg/
g) shown in boxplots for the three different tests (A, B and C) in
the different diagnostic groups (IBD/A, active inflammatory
bowel disease; IBD/R, inflammatory bowel disease in remission;
GI Dis, proven gastrointestinal diseases other than Crohn’s
disease or ulcerative colitis; controls, children with no obvious
gastrointestinal disease).
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Our results showed that all three tests for the measure-
ment of FC showed a high sensitivity (>97%, table 2) to
detect participants with active IBD. A recent
meta-analysis investigated the diagnostic accuracy of FC
in paediatric suspected IBD.8 Pooled data of 715 patients
(394 with IBD, 321 controls) showed a high sensitivity of
98% with a modest specificity of 68% in paediatric
patients with IBD at diagnosis.
There is adequate evidence that in paediatric patients
with IBD FC levels reflect disease activity as measured by
different activity scores such as the modified Lloyd-Still
score,19 the Paediatric Crohn’s Disease Activity Index
(PCDAI)20 or the Paediatric Ulcerative Colitis Index
(PUCAI).10 Tibble et al21 first described that an FC value
of 50 µg/g was a sensitive and specific marker of relapse
in Crohn's disease (CD) and ulcerative colitis (UC)
Table 2 Percentage of children in the four different groups having faecal calprotectin values <50 µg/g (normal), 50–100 µg/g









Test value (µg/g) <50 50–100 >100 <50 50–100 >100 <50 50–100 >100 <50 50–100 >100
Test A 2.3 0.8 96.9 56.5 17.7 25.8 24.4 11.1 64.4 82.1 10.5 7.5
Test B 2.3 2.3 95.4 54.8 12.9 32.3 31.1 20.0 48.9 85.1 10.5 4.5
Test C 1.5 1.5 96.9 45.2 14.5 40.3 24.4 13.3 62.2 62.7 20.9 16.4
GI, gastrointestinal; IBD, inflammatory bowel disease.
Table 3 Panels A-D: Comparison of the three different tests categorizing children according to their faecal calprotectin
concentrations in five categories: normal: 0 – 50 µg/g, borderline: 50 – 100 µg/g, moderately high: 100 – 250 µg/g, high: 250 –
1000 µg/g, very high: >1000 µg/g.
Panel A: Comparison of test A vs. B
0 – 50 50 – 100 100 – 250 250 – 1000 > 1000 Test A
0 – 50 96 6* 2** 104
50 – 100 10* 6 8* 24
100 – 250 3** 10* 20 4* 37
250 – 1000 1** 2** 17* 49 69
> 1000 1** 2** 47* 20 70
Test B 110 25 49 100 20 304
Panel B: Comparison of test A vs. C
0 – 50 50 – 100 100 – 250 250 – 1000 > 1000 Test A
0 – 50 75 22* 5** 2** 104
50 – 100 5* 5 12* 2** 24
100 – 250 1** 2* 12 21* 1** 37
250 – 1000 1** 2** 8* 37 21* 69
> 1000 1** 3** 12* 54 70
Test C 83 31 40 74 76 304
Panel C: Comparison of test B vs. C
0 – 50 50 – 100 100 – 250 250 – 1000 > 1000 Test B
0 – 50 77 26* 5** 1** 1** 110
50 – 100 5* 2 12* 5** 1** 25
100 – 250 2* 18 26* 3** 49
250 – 1000 1** 4* 37 58* 100
> 1000 1** 1** 5* 13 20
Test C 83 31 40 74 76 304
Panel D: Concordance and discrepancies in numbers of children between the three different tests
Concordance 1 category > 1 category
discrepancy(*) discrepancy (**)
Test A vs. Test B 191 102 11
Test A vs. Test C 183 103 18
Test B vs. Test C 147 138 19
* 1 category discrepancy
** more than 1 category discrepancy
Differences of>1 category (**) between two tests are considered as clinically meaningful.
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(sensitivity of 90%, specificity of 83%). Recently
Aomatsu et al22 also showed a good correlation of FC
values and disease activity in paediatric patients deter-
mined by endoscopic activity scores. Four of 130 patients
classified as having active disease based on non-bloody
diarrhoea or abdominal pain had normal or borderline
FC concentrations in all three tests. Pain and diarrhoea
are unspecific and may be related to irritable bowel syn-
drome, lactose intolerance or loss of bile acids, condi-
tions that commonly coexist in patients with IBD and
are unrelated to disease activity.23
In contrast patients with IBD judged by the clinician
as ‘in remission’ showed a high percentage FC values
above 100 µg/g, indicating subclinical intestinal inflam-
mation. Although patients in clinical remission showed
lower FC values than patients with active disease, only
45–56% of patients in remission showed FC values below
the cut-off of 50 µg/g. Normal FC values indicate
mucosal healing during endoscopy24 or microscopic
healing.25 Sipponen and Kolho12 reported that only
35% of children with quiescent IBD had normal or bor-
derline FC values. The low sensitivity of global assess-
ments for CD compared to calprotectin has been shown
in previous studies, in children25 and adults.26 A better
correlation between the disease score and FC concentra-
tions has been reported for patients with UC.10 27 It can
be concluded that in treated patients with IBD FC seems
more sensitive for the detection of intestinal inflamma-
tion compared to clinical judgement and activity scores.
Our study confirmed that elevated FC levels are not
specific for IBD, as there were increased FC levels also in
group 3 (other GI disorders). Elevated FC concentra-
tions have been shown in adults with colorectal cancer
or adenomatous polyps28 and in children with juvenile
polyps29 as well as in some but not all children with
untreated coeliac disease and cow’s milk or multiple
food allergy30 or eosinophilic and lymphocytic colitis.20
With respect to specificity two of the three tests had
<10% of the control children with no obvious GI disease
in the pathological range (>100 µg/g) and another 10%
of the children with borderline values (50–100 µg/g).
Elevated FC levels have been reported in 9 of 126 chil-
dren (7%) with functional GI disorders31 based on the
Rome III criteria.32 Since endoscopies had not been per-
formed in most children in the control group, we
cannot exclude that some of these children with ele-
vated values had minor intestinal inflammation. Test C
had more borderline and increased values in the
control children which could lead to a higher propor-
tion of endoscopies in the clinical setting. However, it
cannot be excluded that the higher values in test C may
be the result of a better recovery rate of calprotectin.
Stool samples were extracted separately for tests A, B
and C from homogenised stool. Commercially available
extraction devices used in FC tests, including the Roche
kit used in the current study, may recover different rates
from the same sample.33 Therefore it is not clear whether
the used kit behaved consistently between the three tests.
To investigate the concordance between the three
tests we categorised the results in five categories with
values of 2, 5 and 20 times the upper limit of normal.
The cut-off for normal values for most tests is considered
to be 50 µg/g, although some studies used 100 µg/g as
upper limit of normal to calculate sensitivity and specifi-
city.8 9 34 In agreement with other authors we charac-
terised values >1000 µg/g as very high levels.10 12 and
made another cut at 250 µg/g. We considered a differ-
ence of more than one category between two tests as
clinically meaningful. There were fewer discrepancies
between tests A and B, compared to A and C or B and C
(table 3). Highly discrepant results cannot be explained
by obtaining the faecal samples from different locations
of the faeces, because a homogenised stool sample was
the basis for all three tests. We did not perform dupli-
cate measurements which eventually could have
improved the concordance.
Since the cut-off values for the three tests are identical
and the values are given as concentrations (µg/g), clini-
cians and patients may assume that the absolute values
are comparable and reliable. In clinical practice a phys-
ician does not even know which test is performed in the
laboratory and what the maximum detection value of
the given test is. Our study showed that the absolute
value for an individual sample markedly differed
between the three tests, particularly for values in the
pathological range. This makes a comparison of values
from different tests not feasible. It is important to
inform the caring physician and the parents/patient
that the absolute values of different tests have to be
interpreted with caution and decreasing value may not
indicate improvement and vice versa.
In conclusion, measurement of FC in paediatric patients
with unspecific symptoms is very helpful in order to avoid
invasive procedure. Normal FC concentrations make the
diagnosis of IBD very unlikely, regardless of which of the
three tests have been used. However, with respect to speci-
ficity and the absolute values in the borderline and patho-
logical range, we found major differences between the
tests under investigation. Therefore, clinical interpretation
of assay results should be made with caution depending
on the assay used. For follow-up measurements and moni-
toring of the efficacy of a therapeutic intervention it is
highly advisable to use the test of the same manufacturer.
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